Azitra, Inc. (NYSEAMERICAN:AZTR – Get Free Report) shares dropped 3.9% on Wednesday . The stock traded as low as $0.48 and last traded at $0.49. Approximately 147,745 shares were traded during trading, a decline of 83% from the average daily volume of 891,624 shares. The stock had previously closed at $0.51.
Azitra Trading Up 2.0 %
Azitra (NYSEAMERICAN:AZTR – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.31. Equities analysts predict that Azitra, Inc. will post -3.06 EPS for the current year.
Azitra Company Profile
Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.
Recommended Stories
- Five stocks we like better than Azitra
- How to Effectively Use the MarketBeat Ratings Screener
- Top-Performing Non-Leveraged ETFs This Year
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- What Are Dividend Challengers?
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
